Year: 2026

Today, the Tallinn Circuit Court handed down a judgement in the case brought by Tallinn University of Technology against AS Tallinna Vesi, partially upholding Tallinna Vesi’s appeal and partially setting aside the judgement of Harju County Court of 25/04/2025, which had found the claim for late payment interest to be justified prior to 15/07/2022. However, the Tallinn Circuit Court also agreed with the county court that the claim by Tallinn University of Technology against Tallinna Vesi may be justified, at least to some extent; the limitation period should not be applied to the claim, and proceedings should continue regarding the amount of the claim. Tanel Kalaus, Attorney-at-Law and authorised representative of Tallinna Vesi, said: “Today’s judgement contains several positive aspects; for example, the circuit court agreed with our position...

Volta Finance Limited (VTA / VTAS)February 2026 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES Guernsey, March 27th, 2026 BNPP AM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for February 2026. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). Performance and Portfolio Activity Dear Investors, Volta Finance posted a net return of -3% for the month of February 2026. For comparison, US High Yield bonds returned +0.2%*** and Euro High Yield bonds achieved +0.3%**** over the same period, while the Morningstar Leveraged Loan indices were down -0.8%*** in the US and –0.5%**** in Europe. Although February was initially characterized by President Trump’s announcement...

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the crystallization, stability, and dermal penetration challenges posed by rapamycin Poster #76929 highlights a qualitative patient and caregiver interview study evaluating the burden of living with porokeratosis, a serious, rare genetic skin disease characterized by numerous pre-cancerous, pruritic lesions and substantial functional and psychosocial burden WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc., (“Palvella” or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and...

– Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life –– Data further demonstrates first-in-class and best-in-disease barzolvolimab profile – HAMPTON, N.J., March 27, 2026 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD) demonstrating profound improvements in patient quality of life (QoL) across all measured domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of CSU, ColdU and SD—the...

SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,188,407 shares of common stock (or pre-funded warrant in lieu thereof) and warrants to purchase up to 6,376,814 shares of common stock, at a combined purchase price of $3.45 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.20 per share, will be exercisable upon issuance and will expire five and one-half years from the Effectiveness Date (as defined below). The private placement is expected to close on or about March 30, 2026, subject to the satisfaction of customary closing...

The annual report and audit report for Virtune AB (Publ) for the financial year 2025 are now available, either via the attached PDF or via our website: https://virtune.com/. AttachmentVirtune annual report 2025

/NOT FOR DISTRIBUTION TO U.S. WIRE SERVICESOR FOR DISSEMINATION IN THE U.S./ TORONTO, March 27, 2026 (GLOBE NEWSWIRE) — Urbana Corporation (TSX & CSE: URB & URB.A) is pleased to announce it will be recognized on The Globe and Mail’s 2026 Report on Business magazine’s seventh annual Women Lead Here list. This annual editorial benchmark identifies top-level Canadian businesses with the highest executive gender diversity. This is Urbana’s fourth time being recognized. The Women Lead Here benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to provide an overview of the largest Canadian corporations with the highest degree of gender diversity among executive ranks. The ranked companies have made tangible and organizational progress related to executive gender parity. “We...

We expect to release the Q1 2026 interim results of DSV A/S in the morning of 29 April 2026. A webcast and conference call will be held at 11:00 am CEST.        At the conference call, Jens H. Lund, Group CEO, and Michael Ebbe, Group CFO, will present the Q1 2026 Interim Financial Report. The presentation will be followed by a Q&A session. Date:                 29 April 2026Time:                 11:00 am CEST To attend the webcast presentation, please go to Webcast presentation – DSV Interim Financial Report Q1 2026 or go to https://investor.dsv.com/. If you wish to ask questions during the conference call, please register through this link: Conference call Q&A – DSV Interim Financial Report Q1 2026. You will receive an email with dial-in telephone numbers. We recommend participants to dial in 15 minutes prior to...

DUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (in Provisional Liquidation) (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has filed a petition in the High Court in Ireland to wind up the Company. An Order was made appointing Damien Murran and Jennifer McMahon, each of Teneo Restructuring (Ireland) Limited (the “Joint Provisional Liquidators”), as Joint Provisional Liquidators to the Company. The petition is due to be heard on April 13, 2026. If a winding up order is made by the High Court, the Joint Provisional Liquidators will be confirmed as Joint Liquidators of the Company, and this will result...